TEV

Teva Pharmaceutical Industries Limited (TEVA) Q1 2026 Earnings

TEVA·Reported April 29, 2026·Before market open

Teva Pharmaceutical Industries Limited reported Q1 2026 revenue of $4.0B (+2.3% YoY), beat analyst consensus of $3.8B by $194.7M. Diluted EPS came in at $0.53 (+1.9% YoY), beat the $0.50 consensus by $0.03.

Revenue
$4.0Bbeat by $194.7M
Consensus: $3.8B
Diluted EPS
$0.53beat by $0.03
Consensus: $0.50
SEC

SEC Filings

Earnings release8-K · 0001171843-26-002796
Quarterly report10-Q · 0001193125-26-191513

Financial Snapshot

Trailing eight quarters through Q1 2026

View all metrics

Q1 2026 Earnings FAQ

Common questions about Teva Pharmaceutical Industries Limited's Q1 2026 earnings report.

Teva Pharmaceutical Industries Limited (TEVA) reported Q1 2026 earnings on April 29, 2026 before market open.

Teva Pharmaceutical Industries Limited reported revenue of $4.0B and diluted EPS of $0.53 for Q1 2026.

Revenue beat the consensus estimate of $3.8B by $194.7M. EPS beat the consensus estimate of $0.50 by $0.03.

Compared to the same quarter a year prior, revenue grew 2.3% from $3.9B a year earlier and diluted EPS grew 1.9% from $0.52.

You can read the 8-K earnings release (0001171843-26-002796) and the 10-Q periodic report (0001193125-26-191513) directly on SEC EDGAR. The filing index links above go to sec.gov.